These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15173553)

  • 1. Persistence of medial hyalinosis of small vessels in an allograft after discontinuation of cyclosporine.
    Bastani B; Amin K; Salinas-Madrigal L
    Ann Pharmacother; 2004; 38(7-8):1322-3. PubMed ID: 15173553
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cyclosporine-induced nephropathy in patients after heart transplantation -- a significant clinical problem].
    Dziewanowski K; Kurowski M; Kopeć E; Busz-Papiez B
    Kardiol Pol; 2006 May; 64(5):522-5. PubMed ID: 16752339
    [No Abstract]   [Full Text] [Related]  

  • 3. Classic lamellar proteinaceous medial hyalinosis of small arteries and arterioles seen in an allograft without cyclosporine exposure.
    Amin K; Salinas-Madrigal L; Bastani B
    Transpl Int; 2005 Jun; 18(6):759-60. PubMed ID: 15910308
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreased nephrotoxicity after the use of a microemulsion formulation of cyclosporine A compared to conventional solution.
    Ahlmén J; Sundberg A; Gustavsson A; Strömbom U
    Transplant Proc; 1995 Dec; 27(6):3432-3. PubMed ID: 8540036
    [No Abstract]   [Full Text] [Related]  

  • 5. Altitude and arteriolar hyalinosis after kidney transplantation.
    Cippà PE; Grebe SO; Fehr T; Wüthrich RP; Mueller TF
    Nephrology (Carlton); 2016 Sep; 21(9):782-4. PubMed ID: 26823025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoral in acute renal transplantation.
    Rutherford PA; Kumar A; Davison A; Morley AR; Thick M; Goodship TH
    Nephrol Dial Transplant; 1996 Jul; 11(7):1496-7. PubMed ID: 8815435
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclosporine dosing.
    Johnston A; Holt DW
    Transplantation; 1995 Dec; 60(11):1376-7. PubMed ID: 8525544
    [No Abstract]   [Full Text] [Related]  

  • 8. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Goldfarb DA
    J Urol; 2005 Jun; 173(6):2106-7. PubMed ID: 15879857
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclosporine nephrotoxicity (chronic arteriolopathy, glomerulopathy)].
    Matsushima H; Hishida A
    Ryoikibetsu Shokogun Shirizu; 1997; (16 Pt 1):553-5. PubMed ID: 9277814
    [No Abstract]   [Full Text] [Related]  

  • 11. Morphologic features of cyclosporin nephrotoxicity.
    D'Agati VD
    Contrib Nephrol; 1995; 114():84-110. PubMed ID: 7587203
    [No Abstract]   [Full Text] [Related]  

  • 12. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
    Coates PT;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significance of laboratory tests for differential diagnosis of acute renal allograft rejection and acute cyclosporine nephrotoxicity].
    Simić-Ogrizović S; Djukanović Lj; Golubović M; DimitrijevićZ ; Mimić-Oka J; Simić T
    Srp Arh Celok Lek; 1994; 122(5-6):133-6. PubMed ID: 17977408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute toxic myopathy due to pyrazinamide in a patient with renal transplantation and cyclosporine therapy.
    Fernández-Solà J; Campistol JM; Miró O; Garcés N; Soy D; Grau JM
    Nephrol Dial Transplant; 1996 Sep; 11(9):1850-2. PubMed ID: 8918638
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation.
    Ling H; Bhidayasiri R
    Mov Disord; 2009 Sep; 24(12):1848-9. PubMed ID: 19606490
    [No Abstract]   [Full Text] [Related]  

  • 17. [Is it possible to prevent kidney problems caused by immunosuppression?].
    Aitio ML
    Duodecim; 2000; 116(5):511-9. PubMed ID: 11787104
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice.
    Campbell SB; Johnson DW
    Transplantation; 2003 Jun; 75(11):1917-8. PubMed ID: 12811260
    [No Abstract]   [Full Text] [Related]  

  • 19. "Recurrence" of cyclosporine nephropathy in a heart transplant recipient.
    Cavallo T; First MR
    Am J Kidney Dis; 1996 Sep; 28(3):466-8. PubMed ID: 8804250
    [No Abstract]   [Full Text] [Related]  

  • 20. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
    J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.